semaglutide and kidney problems in patients with overweight or obesity chronic disease without diabetes: a randomized double-blind placebo-controlled clinical trial significant 24% reduction in kidney

Key findings from OASIS 4 Double-blind, placebo-controlled, 64-week, phase 3 trial (N=307) Mean weight loss: 13.6% (semaglutide) vs 2.2% (placebo) 5% weight loss in 79.2% (semaglutide) vs 31.1% (placebo) Improvements in physical functioning and cardiometabolic markers Serious adverse events were lower in the semaglutide group (3.9% vs 8.8%) This could be a key player particularly among patients who are needle-averse, travel often, or seek simpler dosing options

In conclusion, this study provides further insight in the effects of treatment with NAC and ALC on descending pathways, as well as short- and long-term effects on the spinal cord trauma zone

Mechanisms for establishment of the placental glucocorticoid barrier, a guard for life

Metabolic pathway signatures associated with urinary metabolite biomarkers differentiate bladder cancer patients from healthy controls

There is also a risk of regaining lost weight

In the 1 mg Phase 2 arm, participants lost about 8% of body weight over 48 weeks